IL HB4335

Creates new Section 356z.53 of the Illinois Insurance Code requiring group and individual health insurance policies and managed care plans issued or renewed on or after January 1, 2024 to cover at least one therapeutic equivalent version of vaginal estrogen without cost sharing.

Allows insurers to cover multiple therapeutic equivalent versions of vaginal estrogen but requires at least one to be included in the formulary and covered without cost sharing.

Requires coverage of a specific vaginal estrogen product recommended by a patient's attending provider without cost sharing, if that product is a therapeutic equivalent approved by the FDA.

Exempts coverage from cost-sharing restrictions only to the extent necessary to avoid disqualifying a high-deductible health plan from health savings account eligibility under Internal Revenue Code Section 223.

Applies the vaginal estrogen coverage requirement to state employees, counties, municipalities, and school districts that provide health insurance coverage, and extends similar mandated coverage requirements to health maintenance organizations, limited health service organizations, and voluntary health services plans.